Nifuroxazide prompts antitumor immune response of TCL-loaded DC in mice with orthotopically-implanted hepatocarcinoma

TIESUO ZHAO1,3,4,6*, HUIJIE JIA5*, QIAN CHENG2, YALI XIAO1, MINMING LI1, WENJING REN6, CHEN LI1, YUCHEN FENG1, ZHIWEI FENG1, HUI WANG3,4 and JUNNIAN ZHENG2

1Department of Immunology, Xinxiang Medical University, Xinxiang, Henan 453003; 2 Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu 221002; 3 Research Center for Immunology, School of Basic Medical Sciences, Xinxiang Medical University; 4 Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang Medical University; 5 Department of Pathology, Xinxiang Medical University; 6 Department of Dermatology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China

Received October 28, 2016; Accepted April 13, 2017

DOI: 10.3892/or.2017.5629

Abstract. Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with a poor prognosis and high mortality. At present, vaccination with tumor cell lysate (TCL) loaded dendritic cells (DC) has been shown to be an effective therapy against HCC. However, the ability of promoting the specific T cell immune response is rather weak, influencing the antitumor response. Thus, it is necessary to find a strategy to improve the antitumor effect of TCL-loaded DC. Activation of signal transducer and activator of transcription 3 (STAT3) significantly inhibits antitumor immune response and DC maturity. Nifuroxazide, an antidiarrheal agent, has been proved to directly inhibit STAT3 activation. Thus, we investigated whether nifuroxazide could improve the antitumor immune response in mice vaccinated with TCL-loaded DC. The study provides the theoretical and experimental basis for developing an effective adjuvant for DC vaccine to treat HCC.

Introduction

HCC is one of the most common malignancies worldwide, with a rapidly progressive clinical course (1). Patients with advanced HCC have an average life span of just a few months (2). At present, progress in the early diagnosis and treatment of HCC have increased the mean survival time, but the prognosis is still poor and novel therapeutic strategies are urgently needed (3). As known, the antitumor immune response is functionally impaired in HCC patients and the function of T cell is inhibited (4,5). Thus, it is important to develop a treatment method to enhance the immune response in HCC patients.

Since found in 1973, dendritic cells (DC) pulsed with tumor-associated antigens have been applied as a therapeutic vaccine to tumor patients and they elicited an antitumor immune response (6,7). In addition, DC loaded with tumor cell lysate (TCL), prepared by the artificial lysis of tumor cells, significantly inhibited tumor growth, increased the survival of tumor-born mice and strengthened antitumor cytotoxic activity (8-10). However, it was reported that the application of TCL-loaded DC only elicited weak T cell responses (9). Furthermore, in tumor patients, most DCs are immature cells that do not express costimulatory signals required to promote T cell development.

It was demonstrated that the activation of signal transducer and activator of transcription 3 (STAT3) inhibits DC maturity (11,12). The STATs are related to tumorigenesis and tumor progression, and STAT3 belongs to an important member of the STAT family that is excessively activated in many tumors, including hematological malignancies and solid malignancies (13). The abnormal expression of STAT3 in tumor tissues

Correspondence to: Professor Junnian Zheng, Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China
E-mail: jnzheng@xzhmu.edu.cn

Professor Hui Wang, Research Center for Immunology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
E-mail: wanghui@xxmu.edu.cn

*Contributed equally

Abbreviations: HCC, hepatocellular carcinoma; TCL, tumor cell lysate; DC, dendritic cells; STAT3, signal transducer and activator of transcription 3; NK, natural killer

Key words: HCC, nifuroxazide, STAT3, TCL-loaded DC, antitumor immune response
leaves to tumor cell proliferation, suppression of cell apoptosis and impaired host antitumor immunity (14,15). Thus, blocking STAT3 activation might have antitumor effects that inhibit the growth of human HCC cells including HepG2, PLC/PRF/5 and H7402 and strengthen the function of natural killer (NK) cells in a mouse model of HCC (11,12). Therefore, it is important to develop a new, safer and more effective agent to inhibit the activation of STAT3, which might be applied to treat the HCC patients in the clinic. Nifuroxazide directly inhibited STAT3 thereby inhibiting the survival of multiple myeloma cells (16). Recently, nifuroxazide was also reported to induce apoptosis of breast cancer cells and inhibit pulmonary metastasis in a breast cancer model (17).

Thus, in this study, we observed the effect of combining nifuroxazide and DC pulsed with TCL on the survival rate and lymphocyte infiltration in tumor tissues of an orthotopically implanted hepatocarcinoma model. We found that the combination applied of nifuroxazide and DC pulsed with TCL improved the survival rate, inhibited the tumor growth, but also increased the CD4+ and CD8+ T cell infiltration in tumor tissues.

Materials and methods

Reagents and antibodies. Nifuroxazide was purchased from Shanghai Seebio Biotech, Inc and was preserved at 20 mg/ml solution in dimethyl sulfoxide (DMSO) and stored at -20°C. The cytokines of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-4 and tumor necrosis factor (TNF)-α were purchased from PeproTech Inc. (Rocky Hill, NJ, USA).

Mice. Male C57BL/6 mice, aged 6-8 weeks, were purchased from Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China). All the mice were maintained at 22±2°C within pathogen-free conditions according to the Care and Use of Laboratory Animals of the National Institute of Health Guide.

Cell culture. Human HepG2 cells and the mouse hepatoma cell line H22 were obtained from Professor Xuejian Zhao (Department of Pathophysiology, Prostate Diseases Prevention and Treatment Research Centre, Norman Bethune College of Medicine, Jilin University, Changchun, China). All the cells were propagated in RPMI-1640 media supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco) and cultured in a 5% CO₂ humidified incubator at 37°C.

Cell viability assay. HepG2 cells were plated into 96-well flat-bottom dishes (Corning-Costar) (2x10⁴ cells/well) and cultured for 16 h. Then the cells were treated with different concentrations of nifuroxazide. After 48 and 72 h, 10 µl of CCK8 was added to each well and the cells were incubated for another 4 h, respectively. The viability effects were recorded using a multwell microtiter plate reader (Thermo Fisher Scientific). Each experiment contained three wells and was repeated three times.

Wound healing assay. Cell migration activity was assessed using a wound healing assay. HepG2 cells (3x10⁴ cells/well) were plated into 6-well flat-bottom dishes (Corning-Costar). After culturing for 16 h, the initial gap was established using a micropipette tip and the gap length was measured. At the same time, nifuroxazide was added into the well at doses of 0.25, 0.5, 1, 2 and 4 µg/ml. At 24 h, and 48 h after cultured with nifuroxazide, the residual gap length was recorded, respectively. Each experiment contained three wells and was repeated three times.

Isolation of mouse bone-marrow-derived DCs. Mouse bone-marrow-derived DCs (BMDCs) were isolated from C57BL/6 mice as previously described (18,19). Briefly, on day 0, mice were sacrificed and bone marrow cells were sluced out from the femurs and tibiae and added into ACK lysis buffer (Beyotime Biotechnology, Shanghai, China) to remove erythrocytes. Then the cells were cultured in a 6-well plate using RPMI 1640 medium supplemented with 20 ng/ml GM-CSF and 10% FBS. On day 2, the original medium was replaced with fresh medium including 20 ng/ml GM-CSF. On day 5, half of the medium was replaced with fresh medium including 20 ng/ml IL-4 and 20 ng/ml GM-CSF. On day 7, the cells in plates were harvested. At this point, DCs mainly possessed the characteristic of immature DCs (iDC) and their purity was ≥85%.

Preparation of TCL-pulsed DCs. iDCs (3x10⁶) were loaded with TCL containing 100 µg protein/ml and incubated for 6 h. Then the wells were super-induced by TNF-α at a concentration of 50 ng/ml and then cultured for another 72 h. Finally, the DCs were harvested and the surface molecules of CD80 and CD86 were detected to determine whether DCs were mature.

Preparation of the tumor cell lysate. TCL of H22 was prepared. In brief, cultured H22 cells were collected in phosphate buffered saline (PBS) buffer and lysed by a freeze-thaw cycle five times. Then, TCL were centrifuged for 10 min at 12,000 rpm and the supernatant was gathered with the tumor antigen and stored in a -70°C refrigerator. Finally, the concentration of protein was evaluated using a BSA kit.

Preparation of TCL-pulsed DCs. iDCs (3x10⁶) were loaded with TCL containing 100 µg protein/ml and incubated for 6 h. Then the wells were super-induced by TNF-α at a concentration of 50 ng/ml and then cultured for another 72 h. Finally, the DCs were harvested and the surface molecules of CD80 and CD86 were detected to determine whether DCs were mature.

Mouse experiments. In this study, male C57BL/6 mice were used to establish an orthotopically implanted HCC model and maintained at 22±2°C with a 12 h light/dark cycle. All mice had free access to food and water during the experiments. Briefly, two mice were injected subcutaneously with 1x10⁶ H22 cells. After 2 weeks, the tumors were isolated and cut into small pieces with an equal volume of 1 mm³. The C57/BL6 mice were anesthetized using pentobarbitone at dose of 70 mg/kg body weight. Then, the mice were laparotomized and the fragments of tumor tissue were thrust into livers by forming a 3-mm-long hole.

After 7 days, the mice were randomly divided into four groups including PBS, nifuroxazide, TCL-pulsed DC and nifuroxazide combination with TCL-pulsed DC group. The mice in the PBS group were intraperitoneally injected with 100 µl PBS, mice in the nifuroxazide group were intraperitoneally injected with nifuroxazide at a dose of 200 µg per mouse, mice in the TCL-loaded DC group were intravenously injected with DCs and mice in the combination treatment group were intraperitoneally injected with nifuroxazide at
a dose of 200 µg per mouse plus intravenously injection of DCs. Nifuroxazide was injected once daily and maintained for 7 days. TCL-loaded DCs were injected, respectively, on 7 and 14 days after tumor challenge. The survival rate was recorded each day and the tumor was weighed at 21 days after tumor challenge.

**Immunohistochemistry assay.** At 14 days after treatment, tumor tissues were fixed in 10% neutral formalin for 24 h, and then the tissues were embedded in paraffin and cut into 5 µm-thick sections for next assay as previously described. To analyze the lymphocyte infiltration of tumor tissues, immunohistochemical analyses were carried out using antibodies against CD4 and CD8 (Santa Cruz Biotechnology, Santa Cruz, CA, USA).

**Flow cytometry assay.** The ratios of CD4, CD8 and NK cells in splenocytes were analyzed using flow cytometry. Briefly, at 14 days after treatment, 3 mice from group were randomly sacrificed. The spleens were isolated and homogenized in RPMI-1640, and centrifuged at 2000 rpm for 5 min at 4°C. The precipitates were harvested and lysed the red blood cell using

---

**Figure 1. Effects of nifuroxazide on HCC cell viability.** HepG2 cells were plated into 96-well flat-bottom dishes (2x10⁴ cells/well) and cultured for 16 h. Then the cells were treated with nifuroxazide at different concentrations (0.50, 1, 2, 4, 8, 16 and 32 µg/ml. After 24 and 48 h, 10 µl of CCK8 was added to each well and incubated for 4 h, respectively. Each experiment contained three wells and was repeated three times. (A) The killing effect of nifuroxazide on HepG2. (B) The optical density (OD) value of surviving cells. *P<0.05, **P<0.01.
ACK buffer. The cells were harvested and counted. Then, the
splenocytes were incubated with the following antibodies:
CD3-FITC, CD4-PE, CD8-APC and NK1.1-PE (BioLegend)
at 4°C for 30 min. Finally, the cells were washed and detected
by flow cytometry. Staining score was made according to the
standards of grading: 0, no positive cells; 1, population of
positive cells <1%; 2, population of positive cells >1%, <10%;
3, population of positive cells >10%, <20%; 4, population of
positive cells >20%.

Detection of cytokines. Mouse serum was separated at
21 days after tumor challenge. The samples were centrifuged
at 6,000 rpm for 10 min at 4°C. The levels of interferon
(IFN)-γ, TNF-α or vascular endothelial growth factor
(VEGF) were determined using enzyme-linked immuno-
sorbent assay (ELISA) kit (RayBiotech, Inc.) according to
the manufacturer's directions.

Detection of protein expression. To analyze protein expres-
sion, tumor tissues were lysed using RIPA Lysis Buffer
(Beyotime Institute of Biotechnology, Shanghai, China) and
the expression of various proteins was detected by western
blotting (WB) as previously described (20). The antibodies
were against STAT3, p-STAT3, cleaved caspase-3, MMP2 and
PARP. All the antibodies were purchased from cell signaling
technology except the α-tubulin, which was purchased from
Sigma-Aldrich (St. Louis, MO, USA).

Statistical analysis. Data are shown as the mean ± standard
deviation (SD). The survival of mice in different groups
was determined by the Kaplan-Meier test. Other data were
determined by one-way ANOVA. All statistical analysis was
performed using SPSS software and the statistical differences
were considered at P<0.05.

Results

Nifuroxazide inhibits hepatocellular carcinoma cell inva-
sion and migration. HepG2 cells were treated with different
concentrations (0.5, 1, 2, 4, 8, 16 and 32 µg/ml) of nifuroxa-
zide to investigate its effect on HCCs. Cell proliferation
was detected at 24 and 48 h post-treatment, respectively. The results
showed that 24 h after treatment with nifuroxazide, the cell
viability only was significantly inhibited at the concentration
of 32 µg/ml compared with treatment of medium alone, while
nifuroxazide inhibited cell viability at all tested concentra-
tion at 48 h. These data suggested that nifuroxazide inhibited
HepG2 cell viability time and concentration dependently.
However, nifuroxazide at the doses of 16 and 32 µg/ml showed
similar cell viability (Fig. 1).

Next, we investigated whether nifuroxazide could inhibit
cell migration. As shown in Fig. 2, cell migration was signifi-
cantly inhibited at 24 h after treatment with nifuroxazide
at concentrations of 2 or 4 µg/ml. Although nifuroxazide
significantly inhibited cell migration at the concentrations of
0.50, 1, 2 and 4 µg/ml, respectively, at 48 h, nifuroxazide at the concentrations of 1, 2 or 4 µg/ml had a similar effect on cell migration (Fig. 2).

**Combined application of nifuroxazide and DC pulsed with TCL inhibits tumor growth and increases the survival rate of mice implanted with hepatocarcinoma.** It has been demonstrated that nifuroxazide inhibited myeloid-derived suppressor cell (MDSCs) proliferation (17), thus we detected whether nifuroxazide could enhance the antitumor immune response of TCL-loaded DC in mice with implanted hepatocarcinoma. First, we detected the effect of different dose of nifuroxazide on mice with implanted hepatocarcinoma. We found that nifuroxazide at the dose of 200 µg per mouse showed a preferable treatment effect compared with doses of 100 or 300 µg per mouse (data not shown). Next, we detected whether nifuroxazide at 200 µg per mouse could prompt the antitumor effect of TCL-loaded DC. The results showed that at 40 days post-tumor challenge, both of the survival rates of mice in the nifuroxazide group (50%, n=12) and DC group (33.3%, n=12) were significantly enhanced compared with the control group (25%, n=12). Furthermore, the survival rate of mice in the combination treatment group was highest (58.3%, n=12) compared with the nifuroxazide group or DC group (Fig. 3A).

To further compare the antitumor effect of the combined application of nifuroxazide and TCL-loaded DC, we detected the tumor weight of mice at 21 days after tumor challenge. As shown in Fig. 3B and C, though the tumor growth was significantly inhibited in mice treated with nifuroxazide or TCL-loaded DC, the combined application with nifuroxazide and TCL-loaded DC had a more potent effect on inhibiting tumor growth.

**Combined application of nifuroxazide and TCL-loaded DC increases lymphocyte infiltration in tumor tissues.** Next, we detected CD4+ and CD8+ T lymphocyte infiltration in tumor tissues at 14 days post-tumor-bearing by immunohistochemistry. As shown in Fig. 4, treatment with nifuroxazide or TCL-loaded DC increased the amount of CD4+ and CD8+ T lymphocyte infiltration in tumor tissues compared with control group, respectively. Furthermore, the combination treatment resulted in the greatest amount of lymphocyte infiltration in tumor tissues (Fig. 4).

**Combined application of nifuroxazide and TCL-loaded DC elevated the immune cell response in spleen.** Spleen, as the largest peripheral immune organ, is known to play an irreplaceable role in antitumor immunity. Thus, we assumed that the difference of lymphocyte infiltration in tumor tissues was related to the percentage change of lymphocyte numbers in the spleen. Excitedly, application of nifuroxazide or TCL-loaded DC significantly increased the numbers of CD4+ and CD8+ T lymphocytes in the spleen. Importantly, the combination treatment induced the greatest number of lymphocytes in the spleen, especially CD8+ T lymphocytes compared with the control group, and nifuroxazide or TCL-loaded DC group (Fig. 5A).

In addition, we determined the number of NK cells, which play an important effect on fighting tumors. A similar situation was observed as for T lymphocytes in the spleen. The combination treatment led to the most marked observable increment of NK cells in the spleen (Fig. 5B).
Combined application of nifuroxazide and TCL-loaded DC influences the concentration of cytokines in serum. The cytokines could play a role of eliciting beneficial antitumor effects. Thus, levels of IFN-γ, TNF-α and VEGF in sera were detected by ELISA kits. The results showed that the application of nifuroxazide or TCL-loaded DC increased the levels of IFN-γ and TNF-α, but did not influence the concentration of VEGF. The combined application of nifuroxazide and TCL-loaded DC not only significantly increased the levels of IFN-γ and TNF-α, but also inhibited the release of VEGF compared with the nifuroxazide or TCL-loaded DC group (Fig. 5C-E).

Combined application of nifuroxazide and TCL-loaded DC influences the protein expression in tumor tissues. Many proteins participate in the nascence and development of tumor, therefore, we investigated the expression of some classical proteins related to proliferation, apoptosis and migration in tumor tissues. As shown in Fig. 6, the combined application of nifuroxazide and TCL-loaded DC significantly inhibited the expression of matrix metalloproteinase 2 (MMP-2) that is related with the tumor development and the formed tumor microvasculature, increased the expression of caspase 3 that is known to relate with the tumor cell apoptosis, and reduced the level of poly ADP-ribose polymerase (PARP) which is a substrate incised by caspase protein. In addition, nifuroxazide has been proven to inhibit the STAT3 expression, so we also detected the influence of the combined application of nifuroxazide and TCL-loaded DC on STAT3 expression in tumor tissues. The result showed that the STAT3 expression did not significantly lessen in the nifuroxazide group and combined group, however the phosphorylation STAT3 was obviously inhibited.

**Discussion**

HCC is a frequent human malignancy globally with a poor prognosis due to the absence of effective treatment methods. The antitumor immune responses are often impaired because of the presentation of immunosuppressive factors in the micro-environment of tumor tissues (21). Thus, improving antitumor immune responses would be a useful method to treat HCC. DCs, known as a professional antigen-presenting cells, play an important role in T cell activation. However, in the body of tumor patients exist a large number of immature DC that could not provide the costimulation signals to help T cell development and proliferation (22). Activation of STAT3 has been proved to inhibit the function of immune cells including...
DCs, NK cells, macrophages and T cells (23-26). Furthermore, the activation of STAT3 also played a key role in the progress of HCC (27,28). In a previous study, nifuroxazide, a STAT3 inhibitor, induced tumor cell apoptosis, suppressed the tumor migration and reduced the MDSC infiltration in the lungs of mice in a breast cancer model (17). Furthermore, because single treatment strategy does not have satisfactory effect, combination treatments are increasingly studied. Thus, in this study, we showed that combined application of nifuroxazide and TCL-loaded DC significantly enhanced the survival rate, and inhibited the tumor growth in mice with orthotopically-implanted hepatocarcinomas. Importantly, treatment with nifuroxazide and TCL-loaded DC improved the antitumor immune response by increasing the number of T cells in spleen and enhancing T cell infiltration in tumor tissues.

CD8+ T and NK cells, which have the major antitumor effects in vivo, the function, included directly killing the tumor cells and indirectly damaging the tumor cells by secreting cytokines. It was shown that DC-based vaccine enhanced T cell-mediated cytotoxicity and cytokine secretion (29,30). However, TCL-loaded DC might play a dual role by inducing low antitumor tumor responses and attenuating T cell immune responses (31). In addition, the activation of STAT3 has been demonstrated not only to suppress the DC maturity, but also

**Figure 5.** Combined application of nifuroxazide and TCL-loaded DC increased the ratio of CD4+, CD8+ T cells and NK cells in spleens and raised the concentration of cytokines. At 21 days after tumor challenge, the splenocytes were isolated and the ratios of CD4+, and CD8+ T cells as well as NK cells were detected using flow cytometry. The concentrations of cytokines in serum were detected using ELISA kits. (A) The ratios of CD4+ and CD8+ T cells in spleens. (B) The number of NK cells in spleens. Data are presented as the mean ± SD. (C-E) The concentration of IFN-γ, TNF-α and VEGF. Data are presented as the mean ± SD. *P<0.05, **P<0.01.
to inhibit the proliferation of T lymphocytes, the infiltration of NK cells and the antitumor immune response (23-26). In our experiments, treatment with nifuroxazide or TCL-loaded DC increased the T lymphocyte infiltration in tumor tissues and the ratio of CD8+ T and NK cells in the spleen. Importantly, combination application of nifuroxazide and TCL-loaded DC had the strongest effect on the raising lymphocyte infiltration and the proliferation of T lymphocytes and NK cells. This might be related to the inhibition of p-STAT3 expression. We found that combined application of nifuroxazide and TCL-loaded DC significantly inhibited the expression of p-STAT3 compared with PBS group and nifuroxazide group. Inhibition of the expression of STAT3 increased the T cell infiltration and proliferation (32). Moreover, application of nifuroxazide inhibited the proliferation of MDSC that had an immunosuppressive effect on antitumor responses (17). This might be the method to strengthen the antitumor immune response of TCL-loaded DC by combination application with nifuroxazide.

Furthermore, several immune cells were shown to be involved in antitumor response through secreting some cytokines including IFN-γ and TNF-α (33-35). So the increased number of T lymphocytes and NK cells would lead to higher level of cytokines in the serum. Similar with the antitumor effect, our results showed the combination application of nifuroxazide and TCL-loaded DC significantly raised the concentration of IFN-γ and TNF-α. In addition, VEGF, secreted by tumor cells, induced the hyperplasia of tumor vessels, facilitated the proliferation of tumor cells, and inhibited the tumor apoptosis (36,37). Noteworthy, we found that treatment with nifuroxazide or TCL-loaded DC did not significantly inhibit the level of VEGF, but the combination application of nifuroxazide and TCL-loaded DC had the maximum inhibition effect on the release of VEGF compared with nifuroxazide or TCL-loaded DC group. Since STAT3 signal could promote angiogenesis, we considered that this finding might be related to the lowest expression level of p-STAT3 (38), and the lowest tumor weight.

In addition, the activation of STAT3 signals also promoted tumorigenesis, migration and inhibited cell apoptosis by dysregulating the expression of key proteins including caspase 3, bcl2, MMP2 and MMP9 (39-42). In this study, combination therapy showed a significant inhibitory effect on

Figure 6. Combined application of nifuroxazide and TCL-loaded DC influences the expression of apoptosis and migration related proteins. At 21 days after tumor challenge, 3 mice in each group were randomly sacrificed and the tumor tissues were isolated. The relative expression of proteins in tumor tissues were detected by western blotting. (A) The western blotting results of each protein in every group. (B) The statistical analysis. *P<0.05, **P<0.01.
the expression of MMP2, which promotes tumor migration and progress, and increased the expression of caspase 3, an apoptosis-related protein (43). Apoptosis participates in pathogenesis and progression of cancer. Inducing the expression of apoptosis-related proteins might have antitumor effects and inhibit tumor growth (36,44).

In summary, we demonstrated that combination treatment of nifuraxazole and TCL-loaded DC significantly inhibited tumor growth and prompted the antitumor immune responses in a mouse model of orthotopically-implanted hepatocarcinoma. Nifuraxazole and TCL-loaded DC might be a novel method for treatment of HCC, but further in-depth research is still needed.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (no. 81301947 and 81300442), the Scientific Research Fund of Xinxiang Medical University (no. 2013QN112), the Doctor Launch Fund of Xinxiang Medical University (no. 505016), the platform of collaborative innovation center of Molecular Diagnosis and Laboratory Medicine- Momentous Science and Technology Project of Xinxiang in 2014 and Natural Science Fund for colleges and universities in Jiangsu Province (no. 13KJB320028).

References


